Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study.

BACKGROUND Elevated plasma total homocysteine (tHcy), low B-vitamin intake, and genetic polymorphisms related to tHcy metabolism may play roles in coronary heart disease (CHD). More prospective studies are needed. METHODS AND RESULTS We used a prospective case-cohort design to determine whether tHcy-related factors are associated with incidence of CHD over an average of 3.3 years of follow-up in a biracial sample of middle-aged men and women. Age-, race-, and field center-adjusted CHD incidence was associated positively (P<0.05) with tHcy in women but not men, and CHD was associated negatively (P<0.05) with plasma folate (women only), plasma pyridoxal 5'-phosphate (both sexes), and vitamin supplementation (women only). However, after accounting for other risk factors, only plasma pyridoxal 5'-phosphate was associated with CHD incidence; the relative risk for the highest versus lowest quintile of pyridoxal 5'-phosphate was 0.28 (95% CI=0.1 to 0.7). There was no association of CHD with the C677T mutation of the methylenetetrahydrofolate reductase gene or with 3 mutations of the cystathionine beta-synthase gene. CONCLUSIONS Our prospective findings add uncertainty to conclusions derived mostly from cross-sectional studies that tHcy is a major, independent, causative risk factor for CHD. Our findings point more strongly to the possibility that vitamin B6 offers independent protection. Randomized trials, some of which are under way, are needed to better clarify the interrelationships of tHcy, B vitamins, and cardiovascular disease.

[1]  S. Wannamethee,et al.  Measuring the Prevalence of Disease in Middle-aged British Men , 1999, Journal of the Royal College of Physicians of London.

[2]  J. Manson,et al.  Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. , 1998, JAMA.

[3]  S. Vollset,et al.  Plasma homocysteine levels and mortality in patients with coronary artery disease. , 1997, The New England journal of medicine.

[4]  K. Woo,et al.  Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. , 1997, Circulation.

[5]  J. Cutler,et al.  Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[6]  J. Witteman,et al.  Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. , 1997, JAMA.

[7]  J. Witteman,et al.  Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[8]  Y. Yazaki,et al.  Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. , 1997, Circulation.

[9]  W. Willett,et al.  Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery. , 1997, The American journal of cardiology.

[10]  S. Vasikaran,et al.  Methylenetetrahydrofolate reductase gene and coronary artery disease. , 1997, Circulation.

[11]  L. Taylor,et al.  Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine metabolism and late-onset vascular disease. , 1996, Circulation.

[12]  M. Tsai,et al.  High prevalence of a mutation in the cystathionine beta-synthase gene. , 1996, American journal of human genetics.

[13]  W. Willett,et al.  Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. , 1996, Circulation.

[14]  A. Evans,et al.  Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation. , 1996, Circulation.

[15]  J. Buring,et al.  Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction. A case-control study. , 1996, Circulation.

[16]  M. Tsai,et al.  Simultaneous detection and screening of T833C and G919A mutations of the cystathionine beta-synthase gene by single-strand conformational polymorphism. , 1996, Clinical biochemistry.

[17]  N. Key,et al.  Molecular and biochemical approaches in the identification of heterozygotes for homocystinuria. , 1996, Atherosclerosis.

[18]  H. Morrison,et al.  Serum folate and risk of fatal coronary heart disease. , 1996, JAMA.

[19]  R. Morris,et al.  Serum total homocysteine and coronary heart disease in middle-aged , 1996 .

[20]  W C Willett,et al.  Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate. , 1996, American journal of epidemiology.

[21]  W. Willett,et al.  A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians. , 1996, Journal of the American College of Nutrition.

[22]  A. Folsom,et al.  Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience. , 1996, Journal of clinical epidemiology.

[23]  M. Weijenberg Prospective studies on coronary heart disease in the elderly : the role of classical and new risk factors , 1996 .

[24]  David P Miller,et al.  Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. , 1995, Circulation.

[25]  G. Omenn,et al.  A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. , 1995, JAMA.

[26]  K. Bønaa,et al.  Serum total homocysteine and coronary heart disease. , 1995, International journal of epidemiology.

[27]  J. Selhub,et al.  Homocysteine and coronary artery disease in French Canadian subjects: relation with vitamins B12, B6, pyridoxal phosphate, and folate. , 1995, The American journal of cardiology.

[28]  A. Lindgren,et al.  Plasma homocysteine in acute myocardial infarction: homocysteine‐lowering effect of folic acid , 1995, Journal of internal medicine.

[29]  R. Matthews,et al.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase , 1995, Nature Genetics.

[30]  W. Barlow,et al.  Robust variance estimation for the case-cohort design. , 1994, Biometrics.

[31]  J. Salonen,et al.  Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. , 1994, Atherosclerosis.

[32]  P. Wong,et al.  Thermolabile Defect of Methylenetetrahydrofolate Reductase in Coronary Artery Disease , 1993, Circulation.

[33]  L. Chambless,et al.  The Atherosclerosis Risk in Communities Study: Carotid Artery Intimal‐Medial Wall Thickening and Plasma Homocyst(e)ine in Asymptomatic Adults , 1993 .

[34]  L. Chambless,et al.  Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. , 1993, Circulation.

[35]  W. Willett,et al.  A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. , 1992, JAMA.

[36]  G. Heller,et al.  Comparison of "Rose Questionnaire Angina" to exercise thallium scintigraphy: different findings in males and females. , 1992, Journal of clinical epidemiology.

[37]  L. Chambless,et al.  High‐Resolution B‐Mode Ultrasound Reading Methods in the Atherosclerosis Risk in Communities (ARIC) Cohort , 1991, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[38]  George Howard,et al.  High‐resolution B‐Mode Ultrasound Scanning Methods in the Atherosclerosis Risk in Communities Study (ARIC) , 1991, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[39]  M. Malinow,et al.  Homocyst(e)inemia in daily practice: levels in coronary artery disease , 1990 .

[40]  Aric Invest The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators , 1989 .

[41]  L. Taylor,et al.  Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. , 1989, Circulation.

[42]  A. Folsom,et al.  The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. , 1989, American journal of epidemiology.

[43]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.

[44]  L. A. Smolin,et al.  Measurement of total plasma cysteamine using high-performance liquid chromatography with electrochemical detection. , 1988, Analytical biochemistry.

[45]  W. Willett,et al.  Reproducibility and validity of a semiquantitative food frequency questionnaire. , 1985, American journal of epidemiology.

[46]  W. Gruber,et al.  Reagent for the Enzymatic Determination of Serum Total Triglycerides with Improved Lipolytic Efficiency , 1984, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.

[47]  J. Ziegenhorn,et al.  Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. , 1983, Clinical chemistry.

[48]  J E Frijters,et al.  A short questionnaire for the measurement of habitual physical activity in epidemiological studies. , 1982, The American journal of clinical nutrition.

[49]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[50]  H. Blackburn,et al.  Cardiovascular survey methods. , 1969, Monograph series. World Health Organization.

[51]  A. Clauss,et al.  Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens , 1957 .

[52]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[53]  Agricultural University, , 2022 .